{"product_id":"abcam-ab283867","title":"Abcam, ab283867, Anti-PD-L1 antibody [RM1012] - BSA and Azide free","description":"\u003cp\u003eSize: 100µg \/ 1mg\u003cbr\u003e\nRabbit Recombinant Multiclonal PD-L1 antibody. Carrier free. Suitable for ICC, IP, Flow Cyt, WB, IHC-P, I-ELISA and reacts with Transfected cell line, Human, Recombinant fragment samples.\u003cbr\u003e\nKey facts\u003cbr\u003e\nHost species:Rabbit,\u003cbr\u003e\nClonality:Multiclonal,\u003cbr\u003e\nClone number:RM1012,\u003cbr\u003e\nIsotype:IgG,\u003cbr\u003e\nCarrier free:Yes,\u003cbr\u003e\nReacts with:Human,\u003cbr\u003e\nApplications:ICC, IP, Flow Cyt, IHC-P, I-ELISA, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,\u003cbr\u003e\nImmunogen:The exact immunogen used to generate this antibody is proprietary information.\u003c\/p\u003e\n\n\u003cp\u003eProduct details:\u003cbr\u003e\nab283867 is the carrier-free version of\u003cbr\u003e\nab282458\u003cbr\u003e\nWhat are recombinant multiclonals?\u003cbr\u003e\nRecombinant multiclonals are a mixture of recombinant antibodies co-expressed from a library of heavy and light chains. They offer several advantages including:\u003cbr\u003e\n- The sensitivity of polyclonal antibodies by recognising multiple epitopes\u003cbr\u003e\n- High batch-to-batch consistency and reproducibility\u003cbr\u003e\n- Improved sensitivity and specificity\u003cbr\u003e\n- Long-term security of supply\u003cbr\u003e\n- Animal-free batch production\u003cbr\u003e\nView our range of\u003cbr\u003e\nrecombinant multiclonal antibodies\u003cbr\u003e\nPatented technology\u003cbr\u003e\nOur RabMAb\u003cbr\u003e\ntechnology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to\u003cbr\u003e\nRabMAb® patents\u003cbr\u003e\nConjugation ready\u003cbr\u003e\nOur carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.\u003cbr\u003e\nUse our\u003cbr\u003e\nconjugation kits\u003cbr\u003e\nfor antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.\u003cbr\u003e\nCompatibility\u003cbr\u003e\nThis product is compatible with the Maxpar\u003cbr\u003e\nAntibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar\u003cbr\u003e\nis a trademark of Fluidigm Canada Inc.\u003c\/p\u003e\n\n\u003cp\u003eProperties and Storage Information:\u003cbr\u003e\nForm-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C\u003c\/p\u003e\n\n\u003cp\u003eSupplementary Information:\u003cbr\u003e\nThis supplementary information is collated from multiple sources and compiled automatically.\u003cbr\u003e\nPD-L1 also known as Programmed Death-Ligand 1 or CD274 is a protein involved in immune modulation. Mechanically PD-L1 interacts with its receptors particularly PD-1 to regulate cellular immune responses. This transmembrane protein has a calculated molecular weight of approximately 33 kDa. PD-L1 is expressed on various cell types including tumor cells and immune cells such as dendritic cells macrophages and B cells. Its expression is often upregulated in response to inflammatory cytokines.\u003cbr\u003e\nBiological function summary\u003cbr\u003e\nPD-L1 plays a central role in immune evasion mechanisms utilized by tumors. It is not part of a larger protein complex but directly interacts with PD-1 and CD80. When PD-L1 binds to PD-1 it sends inhibitory signals leading to decreased T cell activation and proliferation allowing cancer cells to avoid immune destruction. PD-L1 expression provides a mechanism for tumors to suppress immune surveillance facilitating tumor progression.\u003cbr\u003e\nPathways\u003cbr\u003e\nPD-L1 is integral to the immune checkpoint pathway which is an important regulator of immune response. The interaction between PD-L1 and PD-1 provides a mechanism for immune tolerance which is part of the broader adaptive immune system pathway. PD-L1 is related to other immune checkpoint proteins such as CTLA-4 in its function to limit autoreactivity and promote immune homeostasis.\u003cbr\u003e\nPD-L1 is most associated with cancer particularly in tumors such as melanoma and non-small cell lung cancer. PD-L1 expression on tumor cells often correlates with poor prognosis. PD-L1 directly interacts with PD-1 in these cancers a target for immunotherapies such as checkpoint inhibitors which aim to block this interaction and restore immune activity against tumors. PD-L1 involvement extends to autoimmune disorders where altered expression can impact tolerance and lead to immune-related tissue damage.\u003c\/p\u003e","brand":"Abcam","offers":[{"title":"Default Title","offer_id":46850176090281,"sku":"ab283867","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/es\/products\/abcam-ab283867","provider":"Iright","version":"1.0","type":"link"}